Vaxart Inc (VXRT)
2.12
-0.12 (-5.36%)
USD |
NASDAQ |
Oct 05, 16:00
2.13
+0.01 (+0.47%)
After-Hours: 17:41
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 268.19M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -67.82% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 564.53 |
| Price to Book Value | 1.874 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.30% |
News
Headline
Wire
Time (ET)
Globe Newswire
09/07 08:30
MT Newswires
09/02 08:21
MT Newswires
09/01 07:06
Globe Newswire
09/01 06:30
Globe Newswire
08/31 16:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/08/2023* | 16:30 EST | Earnings Call | Q2 2023 | -- | -- | -- | |
| 11/04/2022* | -- | Results | Q3 2022 | -- | -0.25 | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.23 | -0.21 | -7.81% | |
| 08/08/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.20 | -0.17 | -15.39% | |
| 02/24/2022 | -- | Results | Q4 2021 | -0.17 | -0.16 | -7.94% | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.14 | -0.14 | 0.00% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.13 | -0.14 | 7.14% |
*Estimated Date/Time
Earnings
Profile
Edit
| Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
| URL | https://www.vaxart.com |
| Investor Relations URL | https://investors.vaxart.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 04, 2022 (est.) |
| Last Earnings Release | Aug. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 09, 2012 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | Nov. 09, 2012 |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 04, 2022.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 92.84M |
| Net Income (TTM) | -92.88M |
| Total Assets (Quarterly) | 181.45M |
| Total Liabilities (Quarterly) | 38.36M |
| Shareholders Equity (Quarterly) | 143.09M |
| Cash from Operations (TTM) | -81.09M |
| Cash from Investing (TTM) | -17.73M |
| Cash from Financing (TTM) | 25.03M |
Ratings
Profile
Edit
| Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
| URL | https://www.vaxart.com |
| Investor Relations URL | https://investors.vaxart.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 04, 2022 (est.) |
| Last Earnings Release | Aug. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 09, 2012 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| VXRT Tweets |